MORRISVILLE, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Science 37, the leader in expanding patient access to clinical trials, and Catalent®, a global leader in enabling pharma, biotech, and consumer health partners to optimize product development and supply, announced a strategic partnership redefining how investigational medicinal products (IMPs) are delivered directly to patients’ homes for clinical research. Through this collaboration, Catalent supports Science 37’s Direct-to-Patient Clinical Trial Site m ...

MORRISVILLE, N.C., April 08, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, today announced the successful completion of its second FDA inspection, reaffirming the quality of its Direct-to-Patient Site for clinical research. The inspection resulted in a No Action Indicated (NAI) categorization, with no objectionable conditions noted and no Form 483 issued. Led by Science 37's internal Quality Assurance & Compliance team, the inspection focused on the company’s ...

文章核心观点 Science 37任命Tyler Van Horn为首席执行官，其过往贡献显著，此次任命将助力公司基于过往成功经验发展，通过创新和提升解决方案交付能力实现增长，引领临床研究进入新阶段 [1][3] 公司动态 - Science 37宣布任命Tyler Van Horn为首席执行官，他曾担任公司首席商务官，推动公司运营卓越和战略方向制定，助力公司增长 [1] - Tyler Van Horn自2021年加入公司后，组建并赋能团队，强调通过居家服务保障患者权益，解决临床研究客户痛点 [2] - Tyler Van Horn表示作为首席执行官将用世界级研究团队和创新解决方案支持赞助商，公司核心是扩大患者参与机会，服务弱势群体，推动医疗变革 [3] 公司介绍 - Science 37通过扩大患者参与临床试验机会加速临床研究，实现更快审批和更好健康结果，其Metasite™和患者招募解决方案可帮助生命科学公司突破传统研究方式 [5] 信息获取 - 如需了解Science 37及其临床研究独特方法，可访问www.science37.com [4][5] - 如需查看Science 37正在招募的研究项目，可访问https://studies.science37.com/current-studies [5] 媒体咨询 - 媒体咨询可联系Science 37，邮箱为pr@science37.com [6]

MORRISVILLE, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, today announced the grand opening of its new, 19,000-square-foot corporate headquarters in Morrisville, North Carolina, in the heart of Research Triangle Park. The new, state-of-the-art facility, will serve as a hub for all Science 37 operations, enabling cross-functional teams with greater opportunities for collaborative problem-solving and integrated solution delivery. Centralizing ope ...

MORRISVILLE, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, disclosed the final figures resulting from its partnership with a biopharmaceutical company focused on infectious disease prevention research. Science 37 contributed to the recruitment and enrollment of an immunocompromised patient cohort for the sponsor's Phase 3 trial. Leveraging its proprietary Virtual Site and Patient Recruitment solutions, Science 37 identified, recruited, medically ...

RESEARCH TRIANGLE PARK, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, has been added to over 20 studies that were lagging in recruitment, helping them to trend back towards their projected targets. Leveraging its proprietary Virtual Site and Patient Recruitment solutions, Science 37 efficiently identified, recruited, medically qualified, and enrolled patients without geographic restrictions. Science 37 has successfully supplemented enrollment in ...

Media Inquiries Science 37 PR@science37.com RESEARCH TRIANGLE PARK, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, has been added to over 20 studies that were lagging in recruitment, helping them to trend back towards their projected targets. Leveraging its proprietary Virtual Site and Patient Recruitment solutions, Science 37 efficiently identified, recruited, medically qualified, and enrolled patients without geographic restrictions. Science 37 ...

About Science 37 Science 37 Holdings, Inc., a leader in enhancing patient access to clinical trials, announced the final enrollment figures from its 20-month engagement with a clinical-stage drug development company advancing novel small molecule therapeutics for systemic neuro-immune disorders. "Traditional recruitment methods are geographically limited, whereas Science 37 can recruit and enroll patients located anywhere, not just within a certain travel radius of a trial site. This significantly broadens ...

Science 37 augmented the recruitment and enrollment activities taking place at study sites nationwide for this ongoing Phase 2 trial evaluating the effects of EP547 in patients with Cholestatic Pruritus due to Primary Biliary Cholangitis (PBC) or Primary Sclerosing Cholangitis. The study protocol mandated a highly specific patient population, requiring participants to undergo evaluation against rigorous inclusion and exclusion criteria. Science 37's Patient Recruitment is available on a standalone basis to ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 001-39727 SCIENCE 37 HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaw ...